Biofrontera Inc(BFRI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BFRI Biofrontera Inc

交易中 02-23 15:53:08 EST

0.8690

-0.0023

-0.26%

最高0.8705	最低0.8091	成交量17.37万
今开0.8610	昨收0.8713	日振幅7.05%
总市值1,012万	流通市值791.23万	总股本1,165万
成交额14.63万	换手率1.91%	流通股本910.51万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BFRI","market":"US","secType":"STK","nameCN":"Biofrontera Inc","latestPrice":0.869,"timestamp":1771879798202,"preClose":0.8713,"halted":0,"volume":173722,"delay":0,"changeRate":-0.0026397337312062076,"floatShares":9105100,"shares":11648323,"eps":-1.8444,"marketStatus":"交易中","change":-0.0023,"latestTime":"02-23 15:53:08 EST","open":0.861,"high":0.8705,"low":0.8091,"amount":146322.4966712,"amplitude":0.070469,"askPrice":0.9016,"askSize":100,"bidPrice":0.8401,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.8444,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"listingDate":1635480000000,"exchange":"NASDAQ","adjPreClose":0.8713,"preHourTrading":{"tag":"盘前","latestPrice":0.866,"preClose":0.8713,"latestTime":"08:58 EST","volume":327,"amount":280.0557165,"timestamp":1771855128818,"change":-0.0053,"changeRate":-0.006083,"amplitude":0.019626},"postHourTrading":{"tag":"盘后","latestPrice":0.878187,"preClose":0.8857,"latestTime":"19:32 EST","volume":33331,"amount":29351.669703,"timestamp":1771633924020,"change":-0.007513,"changeRate":-0.008483,"amplitude":0.07655},"volumeRatio":0.679524,"impliedVol":4.5485,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BFRI","defaultTab":"news","newsList":[{"id":"1180429435","title":"Biofrontera Inc 预计于2026年第三季度提交四肢、颈部和躯干适应症的补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1180429435","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180429435?lang=zh_cn&edition=full","pubTime":"2026-02-17 22:16","pubTimestamp":1771337802,"startTime":"0","endTime":"0","summary":"Biofrontera Inc 计划在2026年第三季度向监管机构提交一份补充新药申请（sNDA），该申请针对的是其在四肢、颈部和躯干方面的适应症扩展。此举标志着公司在拓展其产品应用范围方面迈出了重要一步，有望为相关患者群体提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRIW","BK4007","BFRI"],"gpt_icon":0},{"id":"1184834707","title":"Biofrontera Inc宣布完成用于躯干及四肢光化性角化病的Ameluz®一期药代动力学研究数据库锁定","url":"https://stock-news.laohu8.com/highlight/detail?id=1184834707","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184834707?lang=zh_cn&edition=full","pubTime":"2026-02-17 22:15","pubTimestamp":1771337729,"startTime":"0","endTime":"0","summary":"Biofrontera Inc（纳斯达克代码：BFRI）近日宣布，其针对躯干及四肢光化性角化病的Ameluz®药物一期药代动力学研究已完成数据库锁定。这一关键步骤标志着该临床试验数据收集阶段的正式结束，为后续的数据分析和结果评估奠定了坚实基础。公司表示，此项研究的推进将进一步丰富Ameluz®在皮肤疾病治疗领域的临床应用数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRIW","BFRI"],"gpt_icon":0},{"id":"1161002689","title":"Biofrontera宣布FDA受理Ameluz®光动力疗法治疗浅表基底细胞癌的补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1161002689","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161002689?lang=zh_cn&edition=full","pubTime":"2026-02-11 22:16","pubTimestamp":1770819389,"startTime":"0","endTime":"0","summary":"Biofrontera Inc（简称Biofrontera）近日宣布，美国食品药品监督管理局（FDA）已正式受理其针对Ameluz®光动力疗法（PDT）用于治疗浅表基底细胞癌（sBCC）的补充新药申请（sNDA）。这一重要进展标志着该药物在拓展适应症方面迈出了关键一步，为患者提供了潜在的新治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRIW","BFRI"],"gpt_icon":0},{"id":"1179752893","title":"Biofrontera公布Ameluz®光动力疗法治疗四肢、颈部和躯干光化性角化病三期研究积极结果，达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1179752893","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179752893?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:16","pubTimestamp":1770646572,"startTime":"0","endTime":"0","summary":"Biofrontera Inc (NASDAQ: BFRI) 宣布，其用于治疗四肢、颈部和躯干光化性角化病的Ameluz®光动力疗法在三期临床研究中取得积极结果，成功达到了主要研究终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BK4007","BFRIW"],"gpt_icon":0},{"id":"1178821331","title":"Biofrontera Inc公布2025年第四季度初步营收创纪录，达1700万至1750万美元，同比增长约35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178821331","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178821331?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:33","pubTimestamp":1768311214,"startTime":"0","endTime":"0","summary":"Biofrontera Inc披露了2025财年第四季度的初步营收数据，预计将录得1700万美元至1750万美元的创纪录业绩，较去年同期实现约35%的显著增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BK4007"],"gpt_icon":0},{"id":"1141539493","title":"Biofrontera Inc宣布两项临床研究数据库锁定，助力关键数据与监管里程碑达成","url":"https://stock-news.laohu8.com/highlight/detail?id=1141539493","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141539493?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:50","pubTimestamp":1767880249,"startTime":"0","endTime":"0","summary":"Biofrontera Inc宣布，其两项临床研究已完成数据库锁定，此举将为关键数据的获取及后续监管里程碑的实现提供重要支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRIW","BFRI"],"gpt_icon":0},{"id":"2600196580","title":"Bioage Labs, Inc.盘中异动 下午盘快速跳水5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600196580","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600196580?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:01","pubTimestamp":1767380461,"startTime":"0","endTime":"0","summary":"北京时间2026年01月03日03时01分，Bioage Labs, Inc.股票出现异动，股价大幅跳水5.29%。Bioage Labs, Inc.股票所在的制药行业中，整体跌幅为0.67%。其相关个股中，Shuttle Pharmaceuticals Holdings, Inc.、Ironwood医药、Biofrontera Inc.涨幅较大，Akanda Corp.、Ironwood医药、Biofrontera Inc.较为活跃，换手率分别为193.97%、49.07%、48.54%，振幅较大的相关个股有Ironwood医药、Shuttle Pharmaceuticals Holdings, Inc.、Caring Brands, Inc.，振幅分别为46.88%、30.56%、21.14%。Bioage Labs, Inc.公司简介：Bioage Labs Inc是一家临床阶段的生物制药公司，通过针对人类衰老生物学，开发针对代谢性疾病（如肥胖）的治疗性产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103030101a6ec60b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103030101a6ec60b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BIOA","BFRI"],"gpt_icon":0},{"id":"1137380408","title":"Biofrontera Inc. 完成 Ameluz® 和 Rhodoled® 的 FDA 批准转移及相关知识产权组合的转让","url":"https://stock-news.laohu8.com/highlight/detail?id=1137380408","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137380408?lang=zh_cn&edition=full","pubTime":"2025-12-18 21:50","pubTimestamp":1766065819,"startTime":"0","endTime":"0","summary":"Biofrontera Inc. 完成 Ameluz® 和 Rhodoled® 的 FDA 批准转移及相关知识产权组合的转让","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"1121167657","title":"Biofrontera: 申请旨在扩展 Ameluz 标签，以包括使用其 Bf-Rhodoled 或 Rhodoled Xl 红光灯的 Sbcc 处理的 PDT","url":"https://stock-news.laohu8.com/highlight/detail?id=1121167657","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121167657?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:48","pubTimestamp":1764683293,"startTime":"0","endTime":"0","summary":"Biofrontera: 申请旨在扩展 Ameluz 标签，以包括使用其 Bf-Rhodoled 或 Rhodoled Xl 红光灯的 Sbcc 处理的 PDT","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BK4007"],"gpt_icon":0},{"id":"1148550010","title":"Biofrontera Inc. 提交补充新药申请（SNDA）以治疗表浅性基底细胞癌（SBCC）与 Ameluz®-PDT","url":"https://stock-news.laohu8.com/highlight/detail?id=1148550010","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148550010?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:46","pubTimestamp":1764683213,"startTime":"0","endTime":"0","summary":"Biofrontera Inc. 提交补充新药申请（SNDA）以治疗表浅性基底细胞癌（SBCC）与 Ameluz®-PDT。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRI"],"gpt_icon":0},{"id":"2586089554","title":"Biofrontera Inc.盘中异动 早盘大幅跳水5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586089554","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586089554?lang=zh_cn&edition=full","pubTime":"2025-11-25 22:46","pubTimestamp":1764082007,"startTime":"0","endTime":"0","summary":"北京时间2025年11月25日22时46分，Biofrontera Inc.股票出现异动，股价大幅下跌5.26%。Biofrontera Inc.股票所在的制药行业中，整体涨幅为1.71%。其相关个股中，Esperion Therapeutics, Inc.、Organon & Co.、诺和诺德涨幅较大，Akanda Corp.、Gelteq Limited、Esperion Therapeutics, Inc.较为活跃，换手率分别为4.88%、3.23%、1.16%，振幅较大的相关个股有Esperion Therapeutics, Inc.、Gelteq Limited、Apimeds Pharmaceuticals Us, Inc.，振幅分别为11.36%、11.32%、11.28%。Biofrontera Inc.公司简介：Biofrontera Inc 是一家总部位于美国的生物制药公司，专注于商业化一系列用于治疗皮肤科疾病的药物产品，特别关注光动力疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125224647a4b9b727&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125224647a4b9b727&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BFRI"],"gpt_icon":0},{"id":"2585148628","title":"Biofrontera Inc.盘中异动 股价大跌7.13%报0.751美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585148628","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585148628?lang=zh_cn&edition=full","pubTime":"2025-11-21 04:17","pubTimestamp":1763669836,"startTime":"0","endTime":"0","summary":"北京时间2025年11月21日04时17分，Biofrontera Inc.股票出现波动，股价快速下挫7.13%。截至发稿，该股报0.751美元/股，成交量4.5262万股，换手率0.39%，振幅7.40%。Biofrontera Inc.股票所在的制药行业中，整体跌幅为0.82%。Biofrontera Inc.公司简介：Biofrontera Inc 是一家总部位于美国的生物制药公司，专注于商业化一系列用于治疗皮肤科疾病的药物产品，特别关注光动力疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112104171797762827&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112104171797762827&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BFRI"],"gpt_icon":0},{"id":"1154971158","title":"Biofrontera宣布将Xepi抗生素乳膏的许可出售给Pelthos Therapeutics，交易额可达1,000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154971158","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154971158?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:08","pubTimestamp":1763572105,"startTime":"0","endTime":"0","summary":"11月7日讯 - Biofrontera Inc宣布，将Xepi®抗生素乳膏的许可出售给Pelthos Therapeutics Inc，交易额可达1,000万美元。Biofrontera表示，此项交易预计将使公司实现盈利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRI"],"gpt_icon":0},{"id":"1100661972","title":"Biofrontera：与2024年价格上涨相关的影响在最近几周已开始趋于正常，预计第四季度及全年收入将实现显著增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1100661972","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100661972?lang=zh_cn&edition=full","pubTime":"2025-11-13 21:20","pubTimestamp":1763040016,"startTime":"0","endTime":"0","summary":"Biofrontera：与2024年价格上涨相关的影响在最近几周已开始趋于正常，预计第四季度及全年收入将实现显著增长","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BK4007"],"gpt_icon":0},{"id":"1160367010","title":"Biofrontera Inc. 宣布将 Xepi® 抗生素乳膏的许可出售给 Pelthos Therapeutics Inc.，最高可达 1000 万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160367010","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160367010?lang=zh_cn&edition=full","pubTime":"2025-11-07 21:02","pubTimestamp":1762520543,"startTime":"0","endTime":"0","summary":"Biofrontera Inc. 宣布将 Xepi® 抗生素乳膏的许可出售给 Pelthos Therapeutics Inc.，最高可达 1000 万美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRIW","BFRI"],"gpt_icon":0},{"id":"2579670684","title":"Biofrontera Inc.盘中异动 快速跳水5.66%报1.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579670684","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579670684?lang=zh_cn&edition=full","pubTime":"2025-10-30 23:24","pubTimestamp":1761837867,"startTime":"0","endTime":"0","summary":"北京时间2025年10月30日23时24分，Biofrontera Inc.股票出现异动，股价急速下挫5.66%。截至发稿，该股报1.00美元/股，成交量7.7184万股，换手率0.72%，振幅7.17%。Biofrontera Inc.股票所在的制药行业中，整体涨幅为2.38%。Biofrontera Inc.公司简介：Biofrontera Inc 是一家总部位于美国的生物制药公司，专注于商业化一系列用于治疗皮肤科疾病的药物产品，特别关注光动力疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030232427a6d71ed1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030232427a6d71ed1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BFRI"],"gpt_icon":0},{"id":"1196670928","title":"Biofrontera Inc - 预计资产和人员的完全转移将在2025年第四季度末或2026年第一季度初完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1196670928","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196670928?lang=zh_cn&edition=full","pubTime":"2025-10-23 20:49","pubTimestamp":1761223774,"startTime":"0","endTime":"0","summary":"Biofrontera Inc - 预计资产和人员的完全转移将在2025年第四季度末或2026年第一季度初完成","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRI"],"gpt_icon":0},{"id":"1185650039","title":"Biofrontera Inc宣布Ameluz®(盐酸氨基酮戊酸)外用凝胶10%光动力疗法治疗四肢、颈部和躯干光化性角化病三期研究最后一名患者完成试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1185650039","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185650039?lang=zh_cn&edition=full","pubTime":"2025-09-16 22:30","pubTimestamp":1758033054,"startTime":"0","endTime":"0","summary":"Biofrontera Inc近日宣布，其针对Ameluz®(盐酸氨基酮戊酸)外用凝胶10%光动力疗法的三期临床研究已完成最后一名患者的试验。该研究旨在评估这种光动力疗法治疗四肢、颈部和躯干部位光化性角化病的有效性和安全性。\n随着最后一名受试者完成研究流程，这项重要的三期临床试验正式结束患者招募和治疗阶段。这标志着Biofrontera Inc在推进其Ameluz®产品用于治疗特定部位光化性角化病方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"2562084152","title":"阿尼卡疗法盘中异动 急速下挫5.91%报9.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562084152","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562084152?lang=zh_cn&edition=full","pubTime":"2025-08-25 21:30","pubTimestamp":1756128631,"startTime":"0","endTime":"0","summary":"北京时间2025年08月25日21时30分，阿尼卡疗法股票出现异动，股价大幅下挫5.91%。截至发稿，该股报9.08美元/股，成交量2839股，换手率0.02%，振幅1.40%。机构评级方面，在所有3家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。阿尼卡疗法股票所在的制药行业中，整体涨幅为0.00%。阿尼卡疗法公司简介：Anika Therapeutics Inc 是一家骨科药物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250825213031975fd3c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250825213031975fd3c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BFRI"],"gpt_icon":0},{"id":"1182774938","title":"Biofrontera Inc宣布Ameluz®（盐酸氨基乙酰丙酸）10%外用凝胶治疗中重度寻常痤疮的2B期研究完成最后一名患者出组","url":"https://stock-news.laohu8.com/highlight/detail?id=1182774938","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182774938?lang=zh_cn&edition=full","pubTime":"2025-08-25 20:25","pubTimestamp":1756124753,"startTime":"0","endTime":"0","summary":"Biofrontera Inc宣布Ameluz®（盐酸氨基乙酰丙酸）10%外用凝胶治疗中重度寻常痤疮的2B期研究完成最后一名患者出组","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biofrontera-us.com","stockEarnings":[{"period":"1week","weight":0.1374},{"period":"1month","weight":-0.1134},{"period":"3month","weight":0.1972},{"period":"6month","weight":-0.0809},{"period":"1year","weight":-0.2298},{"period":"ytd","weight":0.5539}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biofrontera Inc.于2015年3月在特拉华州注册成立。该公司是一家总部位于美国的生物制药公司，专门从事用于治疗皮肤病的药物产品的商业化，特别是主要由暴露在阳光下导致皮肤受到阳光伤害的疾病。该公司的许可产品专注于治疗光化性角化病，这是一种有时会导致皮肤癌的皮肤病变。该公司还销售一种用于治疗脓疱病（一种细菌性皮肤感染）的局部抗生素。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.094627},{"month":2,"riseRate":0,"avgChangeRate":-0.162705},{"month":3,"riseRate":0.5,"avgChangeRate":0.15283},{"month":4,"riseRate":0.5,"avgChangeRate":0.037032},{"month":5,"riseRate":0,"avgChangeRate":-0.266269},{"month":6,"riseRate":0.5,"avgChangeRate":-0.026919},{"month":7,"riseRate":0.75,"avgChangeRate":0.187944},{"month":8,"riseRate":0,"avgChangeRate":-0.180573},{"month":9,"riseRate":0.75,"avgChangeRate":0.062418},{"month":10,"riseRate":0.5,"avgChangeRate":-0.098487},{"month":11,"riseRate":0.2,"avgChangeRate":-0.09664},{"month":12,"riseRate":0.4,"avgChangeRate":-0.026989}],"exchange":"NASDAQ","name":"Biofrontera Inc","nameEN":"Biofrontera Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biofrontera Inc(BFRI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Biofrontera Inc(BFRI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Biofrontera Inc,BFRI,Biofrontera Inc股票,Biofrontera Inc股票老虎,Biofrontera Inc股票老虎国际,Biofrontera Inc行情,Biofrontera Inc股票行情,Biofrontera Inc股价,Biofrontera Inc股市,Biofrontera Inc股票价格,Biofrontera Inc股票交易,Biofrontera Inc股票购买,Biofrontera Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biofrontera Inc(BFRI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Biofrontera Inc(BFRI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}